Compare ADMA Biologics Inc (ADMA) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Meta Platforms Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Meta Platforms Inc trades at $605.04 (market cap $1.56T). The key difference: Meta Platforms Inc is far larger — about 732.4× ADMA Biologics Inc's market cap, and Meta Platforms Inc pays a 0.34% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | META | |
|---|---|---|
Market Cap | $2.13B | $1.56T |
Sector | Health | Media |
52-Week High | $20.38 | $790.00 |
52-Week Low | $7.60 | $525.72 |
Enterprise Value | $2.20B | $1.57T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
META trades at $605.36, up 0.84% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $201B, net income margin of 32.84%, and improving cash flow trends. Recent AI developments including the Muse Spark launch and positive analyst sentiment support growth prospects despite legal challenges.
META presents a compelling investment case with strong profitability, AI innovation leadership, and analyst consensus pointing to significant upside. Key risks include regulatory lawsuits and high capital expenditures, but the company's financial strength and market position suggest continued growth potential for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
